RESEARCH PAPER

A methyl-deficient diet fed to rats during the pre- and periconception periods of development modifies the hepatic proteome in the adult offspring

Christopher A. Maloney · Susan M. Hay · Martin D. Reid · Gary Duncan · Fergus Nicol · Kevin D. Sinclair · William D. Rees

Received: 6 October 2011/Accepted: 2 August 2012/Published online: 21 August 2012 © Springer-Verlag 2012

Abstract A methyl-deficient diet (MD) lacking folic acid and the associated methyl donors choline and methionine, fed to the laboratory rat during the periods of oocyte and embryo development, has been shown to programme glucose metabolism in the offspring. The hepatic proteome of the male offspring of female rats fed MD diets for 3 weeks prior to mating and for the first 5 days of gestation has been examined by 2-dimensional gel electrophoresis. Three groups of differentially abundant proteins associated with energy metabolism, amino acid metabolism and antioxidant defence were identified in the soluble proteins extracted from the liver from the MD offspring at both 6 and 12 months of age. Altered mitochondrial activity in other programming models leads to a similar pattern of differential protein abundance. Two of the differentially abundant proteins were identified as GAPDH and PGK-1 by mass spectrometry. Western blotting showed that there

Present Address: C. A. Maloney School of Medical Sciences, Faculty of Medicine, The University of New South Wales, Sydney, NSW 2052, Australia
 S. M. Hay · M. D. Reid · G. Duncan · F. Nicol · W. D. Rees (⊠) The Rowett Institute of Nutrition and Health, The University of Aberdeen, Greenburn Road, Bucksburn, Aberdeen AB21 9SB, Scotland, UK e-mail: w.rees@abdn.ac.uk

K. D. Sinclair

School of Biosciences, University of Nottingham, Sutton Bonington Campus, Loughborough, Leicestershire LE12 5RD, UK were multiple isoforms of both proteins with similar molecular weights but different isoelectric points. The differentially abundant spots reduced in the MD offspring corresponded to minor isoforms of GAPDH and PGK-1. The levels of PPAR-alpha, SREBP and glucocorticoid receptor mRNAs associated with other models of prenatal programming were unchanged in the MD offspring. The data suggest that a diet deficient in folic acid and associated methyl donors fed during the peri-conception and early preimplantation periods of mammalian development affects mitochondrial function in the offspring and that the posttranslational modification of proteins may be important.

 $\label{eq:keywords} \begin{array}{ll} \mbox{Foetal programming} \cdot \mbox{Methylation} \cdot \mbox{PEPCK} \cdot \\ \mbox{Mitochondria} \end{array}$

Abbreviations

ACC-1	Acetyl-CoA carboxylase					
HOMA	Homoeostasis model					
L-CPT-1	Carnitine palmitoyl transferase					
GAPDH	Glyceraldehyde-3-phosphate					
	dehydrogenase					
MD	Methyl deficient					
PEPCK	Phosphoenolpyruvate					
	carboxykinase					
PGC-1α	PPAR- γ co-activator-1 α					
PGK1	Phosphoglycerate kinase					
PPAR- α and PPAR- γ	Peroxisome proliferator-activated					
	receptors alpha and gamma					
SREBP-1c	Sterol response element binding					
	protein					
Udpgdh	UDP-glucose dehydrogenase					
GccR	Glucocorticoid receptor					
oGTT	Oral glucose tolerance test					

Introduction

There is a growing body of evidence to show that an imbalance in the maternal diet during the peri-conception and early preimplantation periods of mammalian development permanently programmes the metabolism of the offspring. The substrates and cofactors involved in methyl metabolism are believed to be especially important during these very early stages of development (Fernandez-Gonzalez et al. 2004; Sinclair et al. 2007b; Hochberg et al. 2010). Studies of animals from several diverse species have shown that methyl-deficient (MD) diets, that is, deficient in folic acid, choline, methionine and vitamins in the B group (folic acid and B_{12}), fed around the time of conception programme the insulin axis and hence glucose metabolism in the offspring. Sheep embryos derived from ewes fed MD diets develop into adults that are heavier, fatter and are insulin-resistant (Sinclair et al. 2007a). A similar change in the insulin axis has also been observed in the male offspring of the laboratory rat exposed to MD diets during oocyte maturation and early development (Maloney et al. 2011). In this model, the Homoeostasis Model Assessment (HOMA) index and peak insulin during an oral glucose tolerance test (oGTT) were increased at 6 months of age, and this change in glucose homoeostasis persisted so that by 12 months of age the peak glucose concentration during oGTT was higher, despite higher peak insulin concentrations. Other treatments that perturb the preimplantation embryo such as assisted reproductive technologies (Scott et al. 2010) and somatic cell nuclear transfer (Tamashiro et al. 2003) have also been reported to change insulin action, producing a similar phenotype to the MD offspring. However, the mechanism underlying the peri-conception programming of glucose metabolism and insulin action is unknown.

The liver has been shown to be an important target organ for metabolic programming in many of the animal models used to demonstrate the developmental origins of health and disease. For example, the expression of key hepatic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK), acyl-CoA carboxylase-1 (ACC-1) and liver carnitine palmitoyl transferase-1 (L-CPT-1) is modified in the offspring of rats fed a low-protein diet during pregnancy (Desai et al. 1997; Zhang and Byrne 2000; Maloney et al. 2003; Rees et al. 2006; Maloney et al. 2007). This programming of the liver extends to the preimplantation period, with a twofold increase in hepatic PEPCK expression in male foetuses of mice fed a low-protein diet during the first 5 days following conception (Kwong et al. 2007). Because the liver has such a central role in metabolic homoeostasis, it is a promising target tissue for programming by early MD diet exposure.

Early preimplantation development is characterised by precise, persistent changes in epigenetic marks that completely reprogramme the mammalian genome by methylation of cytosine residues close to a number of important genes (Santos and Dean 2004). A growing number of studies have associated changes in the methylation of regulatory DNA sequences with developmental programming of offspring metabolism. These sequences include those for integrated viral sequences (Waterland and Jirtle 2003), PPAR-alpha, glucocorticoid receptor (Lillycrop et al. 2005), angiotensin receptor (Bogdarina et al. 2007, 2010), liver X receptor (van Straten et al. 2010) and hepatocyte nuclear factor Hnf4a (Sandovici et al. 2011). Critically, evidence from studies in both sheep and rodents shows that inappropriate methyl nutrition specifically imposed during peri-conception and early preimplantation development persistently modifies the patterns of DNA methylation in adult tissues (Waterland and Michels 2007; Sinclair et al. 2007b). Methylation reactions are also important for the posttranslational modification of proteins; for example, an MD diet fed during dam gestation and lactation has been shown to alter fatty acid oxidation and energy metabolism in the myocardium of rat offspring through imbalanced methylation/acetylation of PGC-1 alpha (Garcia et al. 2011).

In this study, we have compared the proteomic profiles of soluble proteins from the male offspring of rats fed MD diets during the pre- and postconception period with those of control animals. This gives a broad picture of the changes in proteins associated with a wide range of cell function. We have also measured the expression of some of the candidate genes associated with altered epigenetic regulation in other models of prenatal programming to test the possibility that epigenetic marks acquired during the peri-conception and immediate preimplantation stages of development modify hepatic gene expression.

Methods

Animals

All experimental procedures were approved by the Ethical Review Committee of the Rowett Research Institute and conducted in accordance with the UK Animals (Scientific Procedures) Act, 1986. The experiment to produce the offspring and their physiological phenotype has been described previously (Maloney et al. 2011). Briefly, female rats were allocated into two groups fed either a complete semi-synthetic diet (CON) or a methyl-deficient diet (MD) with no folic acid, 0.05 % choline and approximately half the recommended content of methionine for 3 weeks prior to mating and for the first 5 days of gestation. From day 5,

both groups received a complete semi-purified diet until birth, and thereafter, dams and offspring were fed nonpurified diet for the remainder of the experiment (CRM (P) breeder and grower diet 801722, Special Diet Services, Witham Essex UK). Offspring were killed at 6 and 12 months of age, 3 h after being subjected to an oral glucose tolerance test (see Maloney et al. 2011 for details), and samples of the liver were removed, rapidly frozen and stored at -80 °C.

Proteomics

Analysis of the soluble proteome was carried out as described previously (McNeil et al. 2008). Liver samples were chosen randomly from eight male offspring (one per litter) of either the CON or MD groups. Pieces of frozen liver (± 125 mg) were homogenised in 500 µl extraction buffer (pH 7.1) containing 50 mM Tris, 100 mM KCl, 20 % glycerol, 1.4 µM pepstatin A, 1.0 mM PMSF and CompleteTM protease inhibitor cocktail (Boehringer Mannheim). The homogenate was centrifuged for 30 min at 100,000×g at 4 °C (Beckman TL-100 centrifuge). Proteins in the supernatant (300 µg from each extract) were separated in the first dimension on immobilised pH gradient strips (pI 3-10; BioRad, Hemel Hempstead, UK) and in the second dimension on an 18×18 -cm SDS polyacrylamide gel at 200 V for 9.5 h. Molecular weights were determined with a Bio-Rad Precision Plus Protein Mr standard. Gels were stained with colloidal coomassie brilliant blue, washed, scanned and analysed using PDQuest v7 software (BioRad.). Spots corresponding to differentially abundant proteins were excised from the gels using a robotic spot cutter (BioRad), and following trypsin digestion, protein identities were determined by mass spectrometry using either MALDI-TOF (Voyager-DE PRO, Applied Biosystems, Warrington, Cheshire, UK) or LC/ MS/MS (Q-trap Applied Biosystems). The mass spectra were corrected for isotope abundance, and the resulting peptide mass list profiles were analysed using the Matrix Science 'Mascot' web tool (http://www.matrixscience.com). The Mascot database search criteria allowed 1 missed cleavage, carbamidomethyl modification of cysteine; partial oxidation of methionine, a charged state of MH+ and positive identities of at least 20 % matched peptides covering at least 10 % of the protein sequence. Positive matches with proteins in the database were assigned at a probability value of P < 0.05.

Western blotting

Protein samples (200 µg of each extract) were separated by two-dimensional gel electrophoresis (pI 3–10 in the first dimension and in the second dimension on Criterion AnyKd gels (Biorad)) and blotted using the Criterion wet blot system (Biorad). Antibodies were obtained from R&D Systems (Abingdon, Oxfordshire, UK), and conditions for Western blotting were as recommended by the manufacturer. The primary antibodies PGK1 (Cat No AF5455) and GAPDH (Cat No AF5718) were used at a concentration of 0.8 μ g/ml and 0.25 μ g/ml, respectively, and secondary antibody (Cat No HAF109) was used at 0.1 μ g/ml. The blots were visualised by ECL (Imobilon Western Chemiluminescent HRP substrate Cat No WBKLSO500, Millipore, Watford UK) and imaged with a Fuji Imager LAS3000.

Real-time PCR

Total RNA was extracted from samples of liver using the Trizol reagent (Sigma, Poole, Dorset, UK) as described previously (Maloney et al. 2005). Samples of 50 ng total RNA were reverse transcribed using the TaqMan Reverse Transcription Reagents Kit (Applied Biosystems, Warrington, Cheshire, UK) primed with random hexamers. The levels of PPAR-alpha, PPAR-gamma, SREBP-1c, ACC-1, L-CPT-1 and GccR cDNA were measured using the SYBR Green real-time PCR kit (Applied Biosystems) using the primer sequences described previously (Watts et al. 2005; McNeil et al. 2008). The levels of the remaining cDNAs were measured using the TaqMan gene expression assay (PEPCK Assay ID Rn01529009_g1; GAPDH (G3PDH) Assay ID Rn99999916_s1; UGDH Assay ID Rn00580047_m1 from Applied Biosystems). Relative target quantity was calculated from the standard curve, and the results expressed as the ratio of the product relative to the 18S rRNA.

PEPCK assay

PEPCK activity was estimated by the method of (Petrescu et al. 1979) modified for a 96-well plate format. Briefly, samples of liver were homogenised in 10 volumes of icecold buffer (0.25 M Sucrose, 5 mM Hepes (pH 7.4)) and centrifuged at $100,000 \times g$ for 30 min. The assay was conducted in a final volume of 0.25 ml containing; 25 mM Tris–HCl (pH 7.4), 20 mM NaHCO₃, 1 mM MgCl₂, 0.1 mM NADH, 0.5 mM Phosphoenol pyruvate, 2U malate dehydrogenase and 0.025 ml of the homogenate. The reaction was initiated by the addition of 0.15 mM dGTP and monitored by the change in absorption at 340 nm. The background rate was determined in a duplicate set of wells where NaHCO₃ was omitted from the reaction mixture.

GAPDH assay

Glyceraldehyde-3-phosphate-dehydrogenase activity was assayed by the method described in the Worthington

Biochemical Corporation Enzymes manual (www.worthingtonbiochem.com/GAPD/assay.html) modified for a 96-well plate format. Briefly, the assay was conducted in a final volume of 0.25 ml containing 9 mM sodium pyrophosphate (pH 8.5), 18 mM sodium arsenate, 0.25 mM NAD, 3.3 mM DTT and 0.025 ml of the enzyme extract used for the PEPCK assay. The reaction was started by the addition of 0.5 mM Glyceraldehyde-3-phosphate and monitored by the change in absorption at 340 nm.

Statistical analysis

Data are presented as mean \pm SEM. Scans of the proteomic gels were normalised using the PDQuest software to determine the mean corrected spot density. The spot density for each discrete protein on the control gels was compared with the density of the corresponding spot on the MD gels using Student's *t* test. The gene expression data and enzyme activities were analysed by one-way ANOVA followed by Fisher's multiple comparison test (Genstat 7 statistical package, Lawes Agricultural Trust, Rothamsted Experimental Station, Harpenden, Herts, UK).

Results

Proteomics

Soluble proteins prepared from the livers of the male offspring killed at 6 months of age and where possible their male siblings killed at 12 months of age were separated by two-dimensional electrophoresis. Approximately 900 discrete spots were resolved from both sets of samples. Representative gels from 6-month-old offspring are shown in Fig. 1a, b.

Analysis of the spot densities in the liver samples from animals at 6 months of age identified 41 differentially abundant proteins (P < 0.05), 18 upregulated and 23 downregulated in MD compared to CON. These differentially abundant proteins were sequenced by mass spectrometry and are shown grouped by function, in Table 1. The proteins can be classified into three principal groups associated with energy metabolism, antioxidant defence, and amino acid and peptide metabolism. Additionally there were a small number of proteins with no clear functional relationships.

To validate the protein identification by mass spectrometry, duplicate samples were run on similar gels, blotted onto membranes and probed with antibodies specific to two of the differentially abundant proteins PGK-1 (Fig. 1c, d) and GAPDH (Fig. 1e, f). In both cases, these Western blots revealed a number of isoforms of similar molecular weight but differing in their isoelectric points. The differentially abundant spots identified as PGK-1 and GAPDH on the coomassie stained gels both correspond closely to one of the minor isoforms, but because of slight distortions during processing, it was not possible to unambiguously align the differentially expressed proteins with particular spots on the Western blot.

In the samples derived from the livers of the 12-monthold animals, 15 differentially abundant proteins were identified, 7 upregulated and 8 downregulated in MD compared to CON (P < 0.05). These proteins were sequenced by mass spectrometry and are shown grouped by function in Table 2. The proteins can be classified into three principal groups of proteins associated with energy metabolism, antioxidant defence and amino acid and peptide metabolism.

Gene expression

The relative expression of the mRNAs coding for three of the differentially abundant proteins, namely PEPCK, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and UDP-glucose dehydrogenase (Udpgdh) in the livers of 6 month male offspring is shown in Table 3. The mRNAs were unchanged despite changes in the protein levels. There were also no differences in the levels of the mRNAs for PPAR-alpha, PPAR-gamma, SREBP-1c or glucocorticoid receptor (GccR), all of which have been associated with the development of postnatal phenotypes in other animal models of programming. There were also no changes in the levels of mRNA coding for Acc-1 and L-CPT-1 also associated with other programming models.

Enzyme activities

The activity of PEPCK and GAPDH in homogenates prepared from the livers of the male offspring at 6 months of age is shown in Table 4. The activity of both enzymes was unchanged by the maternal diet.

Discussion

This study shows that the abundance of proteins in three different functional groups is changed in the offspring of dams exposed to a methyl-deficient diet during the preconception and preimplantation stages of development. At both 6 and 12 months of age, proteins involved in the processes of energy metabolism, antioxidant defence and amino acid and peptide metabolism are differentially expressed, suggesting that life-long changes in these processes are programmed by exposure to a nutritional insult during the initial cell divisions. The change in proteins associated with energy metabolism is consistent with the



findings of physiological studies conducted whilst these animals were alive, which showed alterations in insulin action and glucose metabolism (Maloney et al. 2011).

Despite changes in the relative abundance of a protein identified as GAPDH in the livers of 6-month-old MD offspring, there was no change in either the mRNA levels or the total enzyme activity. The Western blots show that there are a number of GAPDH isoforms which differ only in their isoelectric points. These are probably caused by modifications, such as acetylation, methylation or phosphorylation, which alter the overall electric charge but have little effect on the apparent molecular weight. The minor GAPDH isoforms located in the region of the spot identified as GAPDH on the gels stained with coomassie blue accounted for between 3 and 5 % of the total antibody binding. This suggests that the differentially abundant protein represents only a small part of the total activity within the cell, whereas the mRNA and enzyme activity reflects the sum of all isoforms of the enzyme. A similar situation probably applies to PGK1, another differentially abundant protein with multiple isoforms. Posttranslational modifications may well underlie the differential abundance of other proteins although this remains to be tested. Specific posttranscriptional modifications of proteins within particular pools or intracellular structures are a critical factor in metabolic channelling and regulation (Guan and Xiong 2011). Although GAPDH is mainly known for its role in glycolysis, there is a growing body of evidence to suggest that this is a multifunctional protein participating in the control of proliferation, apoptosis and transcription (Nicholls et al. 2011). Whilst these differentially abundant protein isoforms may be a relatively small part of the total activity, changes in them may result in much larger effects on metabolism within specific compartments or organelles and may be particularly important in the developmental origins of health and disease.

The mRNA for PEPCK, one of the differentially abundant proteins at 6 months of age, is increased in the foetal liver when animals are exposed to low-protein diet during preimplantation development (Kwong et al. 2007). This enzyme is also changed in the offspring of animals exposed to maternal diets low in protein (LP) or high in fat (HF) throughout gestation. This suggests that modifications of PEPCK may be a common feature of programming models, although there appear to be at least two mechanisms. In the case of the LP model, the changes in PEPCK activity are the result of programmed glucocorticoid signalling (Nvirenda et al. 2001). In the present study, we have been unable to detect a change in the expression of the glucocorticoid receptor (GccR) mRNA (Nyirenda et al. 1998), an observation that would tend to rule out a possible role for glucocorticoids in the early MD model. In the offspring of dams fed the HF diet, there is evidence for a second mechanism involving modifications in the histone code in the livers of the offspring which increase transcription of the PEPCK gene (Strakovsky et al. 2011). However, it is

Table 1 Hepatic proteome of the male offspring at 6 months of age

Mean SEM Mean SEM Energy metabolism 7301 Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12). P04797 62.3 6.5 2.6.1 4.8 0.000 605 UDP-glucose dehydrogenase O70199 82.4 2.0 3.1 1.0 0.001 7011 UPP-glucose 6-dehydrogenase O70199 82.4 2.0 3.1 1.0 0.005 8401 Phosphoglycerate kinase P16617 26.3 1.6.1 16.3.5 46.3 0.035 5702 Phosphoglycerate sinase Q19904 43.2 1.4.1 1.3.8 4.1 0.045 6507 UDP-glucose pyrophosphorylase 2 Q4X50 9.4.5 6.5 6.8.8 0.001 8015 Frictose-bisphosphotal aldolase Q02253 3.0.2 7.2 59.9 9.7 0.013 7404 Furmarue leydrates enricible'd ehydrogenase Q92104 3.5.8 2.8 2.8.4 2.5 0.040 6708 Glucochinase rergulatory protein Q17071 14.7	Spot ID no	Protein identity	NCBI	CON		MD		Р
Dargy metabolism Constraint Output Second Stress Second Stres Second Stress Second Stress <th colspan="2"></th> <th></th> <th>Mean</th> <th>SEM</th> <th>Mean</th> <th>SEM</th> <th></th>				Mean	SEM	Mean	SEM	
Tyon Giyceratekipyde-3-phosphate dehydrogenase (EC 1.2.1.12). P04797 62.3 65.3 26.1 4.8 0.000 6605 UDP-glucose dehydrogenase O70199 8.4 2.0 3.1 0.002 5714 PERCK cytosolic P07379 2.3.2 8.9 3.1 0.025 5702 Phosphoglycerate kinase Q499Q4 4.3.2 1.4.1 1.3.8 4.1 0.036 5702 Phosphoglycerate kinase Q499Q4 4.3.2 1.4.1 1.3.8 4.0 0.019 607 UDP-glucose pyrophosphorylase 2 Q4V80 9.4.5 5.8.8 8.0 0.011 4305 Pyridoxal kinase Q35331 8.3 1.0 1.3.5 2.0 0.019 8602 Methyl-manthe hydratae precursor, mitochondrial QM904 7.3.7 1.5.5 0.023 5408 Fumarth hydratae precursor, mitochondrial QM904 3.8 2.8.4 2.5 0.040 6404 Ghucokinase regulatory protein Q40701 1.4.7 5.2 <td< td=""><td>Energy metal</td><td>polism</td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	Energy metal	polism						
6605 UDP-glucose 6-dehydrogenase O70199 32.3 3.3 17.8 2.7 0.002 7601 UDP-glucose 6-dehydrogenase O70199 8.4 2.0 3.1 1.0 0.015 7514 PERCK cytosolic P0737 23.2 8.9 3.9 3.1 1.0 0.035 8401 Phosphoglucomutase Q499Q4 43.2 14.1 16.35 46.3 0.035 5702 Phosphoglucomutase Q4981 94.5 6.5 6.88 8.0 0.012 4305 Pyridoxal kinase Q4V819 94.5 6.5 6.88 8.0 0.019 8002 Methyl-malonate semi-aldehyde dehydrogenase Q2253 30.2 7.2 59.9 7.0 0.13 7404 Fumarate hydratase precursor, mitochondrial Q5094 7.37 10.5 4.4 4.5 0.040 6061 Nucleoside diphosphate kinase Q19904 3.5 2.8 2.4 4.0 0.041 60763 Callase <	7301	Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12).	P04797	62.3	6.5	26.1	4.8	0.000
7601 UDP-glucose 6-dehydrogenase 070199 8.4 2.0 3.1 1.0 0.015 5714 PERCK cytoshic P07379 2.2 8.9 3.1 1.0 0.026 5701 Phosphoglycemut kinase P16017 26.3 16.1 16.3 8.43 0.026 5702 Phosphoglycemut kinase Q49904 4.3.2 1.4.1 13.8 4.1 0.036 5805 Fructosa-bisphosphate aldolase Q49819 4.5 6.6 8.8 8.0 0.012 4005 Pyridoxal kinase 0.9018 4.3 1.0 1.5 2.0 0.013 5602 Methyl-malonate semi-aldehydrogenase Q92133 3.02 7.2 6.6 8.2 2.4 0.40 2404 S-bisphosphate kinase Q19701 1.7 5.2 2.2 0.004 2404 S-bisphosphate nucleotidase Q921N4 9.2 1.8 1.52 2.6 0.44 6702 Catalase P04762 67.1	6605	UDP-glucose dehydrogenase	O70199	32.3	3.3	17.8	2.7	0.002
5714 PEPCK cytosolic P07379 2.3.2 8.9 3.9 1.1 0.026 8401 Phosphoglycentak kinase P16617 26.2.3 16.1 163.5 4.6.3 0.035 8702 Phosphoglycentak kinase Q499Q4 4.3.2 14.1 13.8 4.1 0.036 8315 Fractose-bisphosphate aldolase Q0884 684.0 107.9 38.3.1 11.3.2 0.043 8405 Vipridoxal kinase Q35311 8.3 1.0 13.5 2.0 0.019 8602 Methyl-malonate semi-aldehyde dehydrogenase Q02253 30.2 7.2 5.9.9 9.7 0.013 8601 Nucleoside diphosphate kinase P19804 35.8 2.8 2.8.4 2.5 0.044 2044 S'-bisphosphate nucleotidase Q97171 4.7 5.2 2.4 0.4 0.016 6703 Gatalase P04762 67.1 8.4 12.8 0.005 7102 Catalase P04762 118.1	7601	UDP-glucose 6-dehydrogenase	O70199	8.4	2.0	3.1	1.0	0.015
8401 Phosphoglycerate kinase P16617 262.3 16.1 163.5 46.3 0.035 5702 Phosphoglucomutase Q499Q4 43.2 14.1 13.8 4.1 0.036 6507 UDP-glucose pyrophosphorylase 2 Q4V8I9 94.5 6.5 68.8 8.0 0.012 4305 Pyridoxal kinase Q55331 8.3 1.0 13.5 2.0 0.019 4304 Funarate hydratase precursor, mitochondrial Q5M964 73.7 10.5 47.4 5.5 0.023 5408 Fumarylacotacetase P19040 35.8 2.8 2.8 0.44 0.04 2404 5'-bisphosphate nucleotidase Q91144 9.2 1.8 15.2 2.6 0.044 702 Catalase P04762 67.1 8.4 12.2 19.8 0.005 7042 Catalase P04762 115.0 9.4 9.1.8 6.6 0.035 703 Glutathione transferase cytosolic P04762 1	5714	PEPCK cytosolic	P07379	23.2	8.9	3.9	1.1	0.026
5702 Piosphoglucomutase Q499Q4 43.2 14.1 13.8 4.1 0.036 8315 Fructose-bisphosphate aldolase P00884 684.0 10.79 383.1 11.3.2 0.043 4305 Pyridoxal kinase Q35331 8.3 1.0 13.5 2.0 0.019 8602 Methyl-malonate semi-aldehyde dehydrogenase Q02253 30.2 7.7 5.9 9.7 0.013 8602 Methyl-malonate semi-aldehyde dehydrogenase Q2203 30.2 7.7 5.0 0.040 90404 S1.8 S2.8 2.8 2.8 0.25 0.040 6001 Nucleoside diphosphare kinase Q21N4 9.2 1.8 15.2 2.6 0.040 6703 Glucokinase regulatory protein Q07071 14.7 5.2 2.4 0.4 0.016 6703 Catalase P04762 67.1 8.4 12.2 2.6 0.02 7010 Catalase P04762 115.0 9.4 91	8401	Phosphoglycerate kinase	P16617	262.3	16.1	163.5	46.3	0.035
8315 Fructose-bisphosphate aldolase P00884 684.0 107.9 383.1 113.2 0.043 6507 UDP-glucose pyrophosphorylase 2 Q4V819 94.5 6.5 6.68.8 8.0 0.012 8602 Methyl-malonate semi-aldehyde dehydrogenase Q02253 30.2 7.2 59.9 9.7 0.013 7404 Fumarylacctoacetase P25093 27.2 6.66 1.56 0.21 0.040 6001 Nucleoside diphosphate kinase P19804 35.8 2.8 2.4 2.5 0.040 64014 5'-bisphosphate nucleotidase Q921N4 9.2 1.8 15.2 2.6 0.044 6708 Glucokinase regulatory protein Q971N4 9.2 1.8 1.52 2.6 0.046 6703 Catalase P04762 67.1 8.4 128.2 19.8 0.016 6703 Glutathione ransferase cytosolic P04762 115.0 9.4 9.8 6.6 0.035 7104 Glutathione f	5702	Phosphoglucomutase	Q499Q4	43.2	14.1	13.8	4.1	0.036
6507 UDP-glucose pyrophosphorylase 2 Q4V819 94.5 6.5 6.8.8 8.0 0.012 4305 Pyridoxal kinase O35331 8.3 1.0 13.5 2.0 0.019 8402 Methyl-malonate semi-aldehyde dehydrogenase Q02253 30.2 7.2 5.0 0.013 7404 Fumarylacetoacetase P25093 27.2 6.6 13.6 2.1 0.040 6001 Nucleoside diphosphate kinase P19804 35.8 2.8 2.8.4 2.2.6 0.044 6708 Glucokinase regulatory protein Q07071 14.7 5.2 2.4 0.4 0.016 Antioxidant Jerner P04762 67.1 8.4 128.2 19.8 0.005 702 Catalase P04762 115.0 9.4 9.18 6.6 0.035 7103 Glutathione-S transferase P04800 11.2 2.5 2.4.2 0.001 704 Thioredoxin reductase (peroxiredoxin-4) Q920V5 5.5.1 5.3	8315	Fructose-bisphosphate aldolase	P00884	684.0	107.9	383.1	113.2	0.043
4305 Pyridoxal kinase 035331 8.3 1.0 13.5 2.0 0.019 8602 Methyl-malonate semi-aldehyde dehydrogenase Q02233 30.2 7.2 59.9 9.7 0.013 7404 Fumarab hydratse precursor, mitochondrial Q5M964 7.7 10.5 47.4 5.5 0.023 5408 Fumarylacetoacetase P25093 27.2 6.6 13.6 2.1 0.040 6001 Nuclcoside diphosphate kinase P19804 35.8 2.8 2.8.4 2.5 0.040 6708 Glucokinase regulatory protein Q07071 1.4.7 5.2 2.4 0.4 0.016 6703 Catalase P04762 67.1 8.4 128.2 19.8 0.005 7103 Glutathione transferase cytosolic P04906 11.2 2.5 2.4.2 0.0013 7104 Glutathione transferase P08009 18.8 4.9 5.7 2.0 0.013 7104 Glutathione transferase P08009 18.8 4.9 5.7 2.0 0.013 7104 <td>6507</td> <td>UDP-glucose pyrophosphorylase 2</td> <td>Q4V8I9</td> <td>94.5</td> <td>6.5</td> <td>68.8</td> <td>8.0</td> <td>0.012</td>	6507	UDP-glucose pyrophosphorylase 2	Q4V8I9	94.5	6.5	68.8	8.0	0.012
8602 Methyl-malonate semi-aldehyde dehydrogenasc Q02253 30.2 7.2 59.9 9.7 0.013 7404 Fumarylacetoacetase P25093 27.2 6.6 13.6 2.1 0.040 6001 Nucleoside diphosphate kinase P19804 35.8 2.8 2.5 0.040 6708 Glucokinase regulatory protein Q07071 1.4 5.2 2.6 0.044 6708 Glucokinase regulatory protein Q07071 1.4 5.2 2.6 0.044 6702 Catalase P04762 67.1 8.4 128.2 19.8 0.005 702 Catalase P04762 418.1 59.1 270.3 19.1 0.016 6703 Catalase P04762 115.0 9.4 9.8 6.6 0.035 7104 Glutathione-Stransferase cytosolic P04906 11.8 4.9 5.7 2.0 0.013 7044 Glutathione-Stransferase Q64011 15.4 2.6 8.7 <t< td=""><td>4305</td><td>Pyridoxal kinase</td><td>O35331</td><td>8.3</td><td>1.0</td><td>13.5</td><td>2.0</td><td>0.019</td></t<>	4305	Pyridoxal kinase	O35331	8.3	1.0	13.5	2.0	0.019
7404 Fumarate hydratase precursor, mitochondrial Q5M964 7.3.7 10.5 47.4 5.5 0.023 5408 Fumarylacetoacetase P25093 27.2 6.6 13.6 2.1 0.040 6001 Nucleoside diphosphate kinase P19804 35.8 2.8 28.4 2.5 0.040 6001 Sickosinase regulatory protein Q07071 14.7 5.2 2.4 0.4 0.016 Arnitoxidant defence T T 5.2 2.4 0.4 0.005 702 Catalase P04762 418.1 59.1 270.3 19.1 0.016 6703 Catalase P04762 115.0 9.4 9.8 6.6 0.035 7104 Glutathione-Stransferase cytosolic P04906 11.2 2.5 2.4 2.0 0.013 704 Thioredoxin reductase (peroxiredoxin-4) Q920V5 55.1 5.3 33.9 7.5 0.019 4106 Peroxiredoxin-6 (EC 1.11.1.15) Q524 19	8602	Methyl-malonate semi-aldehyde dehydrogenase	Q02253	30.2	7.2	59.9	9.7	0.013
5408 Fumarylacetoacetase P25093 27.2 6.6 13.6 2.1 0.040 6001 Nucleoside diphosphate kinase P19804 35.8 2.8 2.8 2.5 0.040 2404 5'-bisphosphate nucleotidiase Q971N4 9.2 1.8 15.2 2.6 0.044 6708 Glucokinase regulatory protein Q07071 14.7 5.2 2.4 0.4 0.016 Antioxidant defence 702 Catalase P04762 115.0 9.4 91.8 0.66 0.035 7002 Catalase P04762 115.0 9.4 91.8 6.6 0.035 7103 Glutathione-transferase cytosolic P04906 11.2 2.5 24.2 0.001 704 Thioredoxin-reductase (peroxiredoxin-4) Oy2075 5.51 5.3 3.9 7.5 0.019 Amino acid and peptide metabolism 0 2.7 2.7.9 2.8 0.013 7010 Carbamoyl-phosphate synthetase P07756	7404	Fumarate hydratase precursor, mitochondrial	Q5M964	73.7	10.5	47.4	5.5	0.023
6001 Nucleoside diphosphate kinase P19804 35.8 2.8 28.4 2.5 0.040 2404 5'-bisphosphate nucleotidase Q97LIN4 9.2 1.8 15.2 2.6 0.044 6708 Glucokinase regulatory protein Q07071 1.4.7 5.2 2.4 0.4 0.016 Antioxidant defence P04762 67.1 8.4 128.2 19.8 0.005 702 Catalase P04762 67.1 8.4 128.2 19.8 0.005 7002 Catalase P04762 418.1 59.1 27.03 19.1 0.016 6703 Catalase P04906 11.2 2.5 2.4 4.2 0.008 7104 Glutathione-S transferase P08009 18.8 4.9 5.7 2.0 0.013 7004 Thioredoxin reductase (peroxiredoxin-4) Q920V5 55.1 5.3 33.9 7.5 0.019 4506 Selenium binding protein Q82VIF7 149.0 2.7 <td>5408</td> <td>Fumarylacetoacetase</td> <td>P25093</td> <td>27.2</td> <td>6.6</td> <td>13.6</td> <td>2.1</td> <td>0.040</td>	5408	Fumarylacetoacetase	P25093	27.2	6.6	13.6	2.1	0.040
2404 5'-bisphosphate nucleotidase Q9Z1N4 9.2 1.8 15.2 2.6 0.044 6708 Glucokinase regulatory protein Q07071 14.7 5.2 2.4 0.4 0.016 Antioxidant defence Valuational defence Valuational	6001	Nucleoside diphosphate kinase	P19804	35.8	2.8	28.4	2.5	0.040
6708 Glucokinase regulatory protein Q07071 14.7 5.2 2.4 0.4 0.016 Antioxidant defence 7702 Catalase P04762 67.1 8.4 128.2 19.8 0.005 702 Catalase P04762 418.1 59.1 270.3 19.1 0.016 6703 Catalase P04762 115.0 9.4 91.8 6.6 0.035 7103 Glutathione transferase cytosolic P04906 11.2 2.5 24.2 4.2 0.0013 7004 Thioredoxin reductase (peroxiredoxin-4) Q9Z0V5 55.1 5.3 33.9 7.5 0.019 4504 Selenium binding protein Q8VIPT 14.9.7 8.7 200.2 2.5.3 0.047 4106 Peroxiredoxin-6 (EC 1.11.1.15) O35244 19.0 2.7 2.7.9 2.8 0.013 7001 Carbamoyl-phosphate synthetase P07756 8.1 1.3 30.3 9.4 0.018 502 Carbamoyl-phosph	2404	5'-bisphosphate nucleotidase	Q9Z1N4	9.2	1.8	15.2	2.6	0.044
Antioxidant defence 7702 Catalase P04762 67.1 8.4 128.2 19.8 0.005 7602 Catalase P04762 418.1 59.1 270.3 19.1 0.016 6703 Catalase P04762 418.1 59.1 270.3 19.1 0.016 6703 Catalase P04762 418.1 59.1 270.3 19.1 0.016 6703 Glutathione transferase cytosolic P04906 11.2 2.5 24.2 4.2 0.008 7104 Glutathione-S transferase P08009 18.8 4.9 5.7 2.0 0.013 7004 Thioredoxin reductase (peroxiredoxin-4) Q820V5 55.1 5.3 33.9 7.5 0.019 4504 Selenium binding protein Q8VIF7 149.7 8.7 2.0 0.21 18.2 3.0 0.013 7010 Crysteine sulphinic acid decarboxylase Q64611 15.4 2.6 8.7 2.4 0.048 2026 3-hydroxyanthranilate 3.4-dioxygenase P07756 8.1 1.3 3	6708	Glucokinase regulatory protein	Q07071	14.7	5.2	2.4	0.4	0.016
7702 Catalase P04762 67.1 8.4 128.2 19.8 0.005 7602 Catalase P04762 418.1 59.1 270.3 19.1 0.016 6703 Catalase P04762 418.1 59.1 270.3 19.1 0.016 6703 Catalase P04762 115.0 9.4 91.8 6.6 0.035 7103 Glutathione transferase cytosolic P049069 11.8 4.9 5.7 2.0 0.013 7104 Glutathione-S transferase P08009 18.8 4.9 5.7 0.019 4504 Selenium binding protein Q8VIF7 149.7 8.7 200.2 25.3 0.047 4106 Peroxiredoxin-6 (EC 1.11.1.15) O35244 19.0 2.7 2.9 2.8 0.013 7901 Carbamoyl-phosphate synthetase P04756 8.1 1.3 30.3 9.4 0.018 5002 Carbamoyl-phosphate synthetase P07756 8.1 1.3 30.3 9.4 0.012 5302 Arginase P07824	Antioxidant d	lefence						
7602 Catalase P04762 418.1 59.1 270.3 19.1 0.016 6703 Catalase P04762 115.0 9.4 91.8 6.6 0.035 7103 Glutathione transferase cytosolic P04906 11.2 2.5 24.2 4.2 0.008 7104 Glutathione-S transferase P08009 18.8 4.9 5.7 2.0 0.013 7004 Thioredoxin reductase (peroxiredoxin-4) Q9Z0V5 55.1 5.3 33.9 7.5 0.017 4504 Selenium binding protein Q8VIF7 149.7 8.7 200.2 25.3 0.047 4106 Peroxiredoxin-6 (EC 1.11.1.15) O35244 19.0 2.7 2.7 2.8 0.018 Amino acid and peptide metabolism 6602 Cysteine sulphinic acid decarboxylase Q64611 15.4 2.6 8.7 2.4 0.048 2006 3-hydroxyanthranilate 3,4-dioxygenase P07756 8.1 1.3 30.3 9.4 0.018 5902 Carbamoyl-phosphate synthetase P07756 7.5 1.8 15.0	7702	Catalase	P04762	67.1	8.4	128.2	19.8	0.005
6703 Catalase P04762 115.0 9.4 91.8 6.6 0.035 7103 Glutathione transferase cytosolic P04906 11.2 2.5 24.2 4.2 0.008 7104 Glutathione-S transferase P08009 18.8 4.9 5.7 2.0 0.013 7004 Thioredoxin reductase (peroxiredoxin-4) Q9Z0V5 55.1 5.3 33.9 7.5 0.019 4504 Selenium binding protein Q8VIF7 149.7 8.7 200.2 2.5.3 0.047 Anino acid and peptide metabolism Peroxiredoxin-6 (EC 1.11.15) O35244 19.0 2.7 2.7.9 2.8 0.013 7001 Carbamoyl-phosphate synthetase Q64611 15.4 2.6 8.7 2.4 0.048 2206 3-hydroxyanthranilate 3,4-dioxygenase P07756 8.1 1.3 30.3 9.4 0.018 5902 Carbamoyl-phosphate synthetase P07756 8.1 1.3 30.3 0.44 0.006 5302 Arginase P07824 69.5 9.0 41.6 9.6 0	7602	Catalase	P04762	418.1	59.1	270.3	19.1	0.016
7103 Glutathione transferase cytosolic P04906 11.2 2.5 24.2 4.2 0.008 7104 Glutathione-S transferase P08009 18.8 4.9 5.7 2.0 0.013 7004 Thioredoxin reductase (peroxiredoxin-4) Q920V5 55.1 5.3 33.9 7.5 0.019 4504 Selenium binding protein Q8VIF7 149.7 8.7 200.2 25.3 0.047 4106 Peroxiredoxin-6 (EC 1.11.1.15) O3524 19.0 2.7 27.9 2.8 0.019 <i>Amino acid and peptide metabolism</i> 0 Cysteine sulphinic acid decarboxylase Q64611 15.4 2.6 8.7 2.4 0.048 2206 3-hydroxyanthranilate 3,4-dioxygenase P06756 8.1 1.3 30.3 9.4 0.018 5902 Carbamoyl-phosphate synthetase P07756 7.5 1.8 15.0 2.9 0.023 908 Carbamoyl-phosphate synthetase P07824 64.5 9.0 41.6 9.6 0.028 6504 Homogentisate 1,2-dioxygenase Q6AYR0 12.4	6703	Catalase	P04762	115.0	9.4	91.8	6.6	0.035
7104 Glutathione-S transferase P08009 18.8 4.9 5.7 2.0 0.013 7004 Thioredoxin reductase (peroxiredoxin-4) Q9Z0V5 55.1 5.3 33.9 7.5 0.019 4504 Selenium binding protein Q8VIF7 149.7 8.7 200.2 25.3 0.047 4106 Peroxiredoxin-6 (EC 1.11.1.15) O35244 19.0 2.7 27.9 2.8 0.019 Amino acid and peptide metabolism 6602 Cysteine sulphinic acid decarboxylase Q64611 15.4 2.6 8.7 2.4 0.048 2206 3-hydroxyanthranilate 3,4-dioxygenase P07756 8.1 1.3 30.3 9.4 0.018 5902 Carbamoyl-phosphate synthetase P07756 7.5 1.8 15.0 2.9 0.023 908 Carbamoyl-phosphate synthetase P07756 8.0 3.9 0.5 0.3 0.044 2068 Dipeptidase 3 (rat) Q5U2X4 6.4 0.7 8.6 0.4 0.006 5302 Arginase P07824 69.5 9.0 41.6	7103	Glutathione transferase cytosolic	P04906	11.2	2.5	24.2	4.2	0.008
Thioredoxin reductase (peroxiredoxin-4) Q9Z0V5 55.1 5.3 33.9 7.5 0.019 4504 Selenium binding protein Q8VIF7 149.7 8.7 200.2 25.3 0.047 4106 Peroxiredoxin-6 (EC 1.11.1.15) O35244 19.0 2.7 27.9 2.8 0.019 Amino acid and peptide metabolism 6602 Cysteine sulphinic acid decarboxylase Q64611 15.4 2.6 8.7 2.4 0.048 2206 3-hydroxyanthranilate 3.4-dioxygenase P46953 9.0 2.1 18.2 3.0 0.013 7901 Carbamoyl-phosphate synthetase P07756 8.1 1.3 30.3 9.4 0.018 502 Carbamoyl-phosphate synthetase P07756 8.0 3.9 0.5 0.3 0.044 2608 Dipeptidase 3 (rat) Q5U2X4 6.4 0.7 8.6 0.4 0.006 5302 Arginase Q6AYR0 12.4 2.6 21.7 3.7 0.032 1007	7104	Glutathione-S transferase	P08009	18.8	4.9	5.7	2.0	0.013
4504 Selenium binding protein Q8VIF7 149.7 8.7 200.2 25.3 0.047 4106 Peroxiredoxin-6 (EC 1.11.1.15) O35244 19.0 2.7 27.9 2.8 0.019 Amino acid and peptide metabolism 6602 Cysteine sulphinic acid decarboxylase Q64611 15.4 2.6 8.7 2.4 0.048 2206 3-hydroxyanthranilate 3,4-dioxygenase P46953 9.0 2.1 18.2 3.0 0.013 7901 Carbamoyl-phosphate synthetase P07756 8.1 1.3 30.3 9.4 0.018 5902 Carbamoyl-phosphate synthetase P07756 7.5 1.8 15.0 2.9 0.023 908 Carbamoyl-phosphate synthetase P07756 8.0 3.9 0.5 0.3 0.044 2608 Dipeptidase 3 (rat) Q5U2X4 64.4 0.7 8.6 0.4 0.002 5302 Arginase Q6AYR0 12.4 2.6 21.7 3.7 0.032 Miscellaneous 1007 BAB24222 (Mus musculus) UNK 4.8 0.7 <	7004	Thioredoxin reductase (peroxiredoxin-4)	Q9Z0V5	55.1	5.3	33.9	7.5	0.019
4106 Peroxiredoxin-6 (EC 1.11.1.15) O35244 19.0 2.7 27.9 2.8 0.019 Amino acid and peptide metabolism 6602 Cysteine sulphinic acid decarboxylase Q64611 15.4 2.6 8.7 2.4 0.048 2206 3-hydroxyanthranilate 3,4-dioxygenase P46953 9.0 2.1 18.2 3.0 0.013 7901 Carbamoyl-phosphate synthetase P07756 8.1 1.3 30.3 9.4 0.018 5902 Carbamoyl-phosphate synthetase P07756 7.5 1.8 15.0 2.9 0.023 908 Carbamoyl-phosphate synthetase P07756 8.0 3.9 0.5 0.3 0.044 2608 Dipeptidase 3 (rat) Q512X4 6.4 0.7 8.6 0.4 0.0028 5302 Arginase Q6AYR0 12.4 2.6 21.7 3.7 0.023 Miscellaneous Miscellaneous UNK 4.8 0.7 7.8 1.2 0.020 1203 Annexin IV (36-kDa zymogen granule membrane) Q5U362 15.1 2.2 20.2	4504	Selenium binding protein	Q8VIF7	149.7	8.7	200.2	25.3	0.047
Amino acid and peptide metabolism 6602 Cysteine sulphinic acid decarboxylase Q64611 15.4 2.6 8.7 2.4 0.048 2206 3-hydroxyanthranilate 3,4-dioxygenase P46953 9.0 2.1 18.2 3.0 0.013 7901 Carbamoyl-phosphate synthetase P07756 8.1 1.3 30.3 9.4 0.018 5902 Carbamoyl-phosphate synthetase P07756 7.5 1.8 15.0 2.9 0.023 908 Carbamoyl-phosphate synthetase P07756 8.0 3.9 0.5 0.3 0.044 2608 Dipeptidase 3 (rat) Q5U2X4 6.4 0.7 8.6 0.4 0.006 5302 Arginase P07824 69.5 9.0 41.6 9.6 0.028 6504 Homogentisate 1,2-dioxygenase Q6AYR0 12.4 2.6 21.7 3.7 0.032 1203 Annexin IV (36-kDa zymogen granule membrane) Q5U362 15.1 2.2 20.2 1.3 0.038 2706 Choline dehydrogenase Q6UPE0 5.6 0.5	4106	Peroxiredoxin-6 (EC 1.11.1.15)	035244	19.0	2.7	27.9	2.8	0.019
6602 Cysteine sulphinic acid decarboxylase Q64611 15.4 2.6 8.7 2.4 0.048 2206 3-hydroxyanthranilate 3,4-dioxygenase P46953 9.0 2.1 18.2 3.0 0.013 7901 Carbamoyl-phosphate synthetase P07756 8.1 1.3 30.3 9.4 0.018 5902 Carbamoyl-phosphate synthetase P07756 7.5 1.8 15.0 2.9 0.023 908 Carbamoyl-phosphate synthetase P07756 8.0 3.9 0.5 0.3 0.044 2608 Dipeptidase 3 (rat) Q5U2X4 6.4 0.7 8.6 0.4 0.006 5302 Arginase Q6AYR0 12.4 2.6 21.7 3.7 0.032 Miscellaneous UO7 BAB24222 (Mus musculus) UNK 4.8 0.7 7.8 1.2 0.020 1203 Annexin IV (36-kDa zymogen granule membrane) Q5U362 15.1 2.2 20.2 1.3 0.038 2706 Choline dehydrogenase Q6UPE0 5.6 0.5 8.6 1.1 0.01	Amino acid a	nd peptide metabolism						
2206 3-hydroxyantranilate 3,4-dioxygenase P46953 9.0 2.1 18.2 3.0 0.013 7901 Carbamoyl-phosphate synthetase P07756 8.1 1.3 30.3 9.4 0.018 5902 Carbamoyl-phosphate synthetase P07756 7.5 1.8 15.0 2.9 0.023 908 Carbamoyl-phosphate synthetase P07756 8.0 3.9 0.5 0.3 0.044 2608 Dipeptidase 3 (rat) Q5U2X4 6.4 0.7 8.6 0.4 0.006 5302 Arginase P07824 69.5 9.0 41.6 9.6 0.028 6504 Homogentisate 1,2-dioxygenase Q6AYR0 12.4 2.6 21.7 3.7 0.032 1007 BAB24222 (Mus musculus) UNK 4.8 0.7 7.8 1.2 0.020 1203 Annexin IV (36-kDa zymogen granule membrane) Q5U362 15.1 2.2 20.2 1.3 0.038 2706 Choline dehydrogenase Q6UPE0 5.6 0.5 8.6 1.1 0.016	6602	Cysteine sulphinic acid decarboxylase	Q64611	15.4	2.6	8.7	2.4	0.048
7901 Carbamoyl-phosphate synthetase P07756 8.1 1.3 30.3 9.4 0.018 5902 Carbamoyl-phosphate synthetase P07756 7.5 1.8 15.0 2.9 0.023 908 Carbamoyl-phosphate synthetase P07756 8.0 3.9 0.5 0.3 0.044 2608 Dipeptidase 3 (rat) Q5U2X4 6.4 0.7 8.6 0.4 0.006 5302 Arginase P07824 69.5 9.0 41.6 9.6 0.028 6504 Homogentisate 1,2-dioxygenase Q6AYR0 12.4 2.6 21.7 3.7 0.032 <i>Miscellaneous</i> I UNK 4.8 0.7 7.8 1.2 0.020 1203 Annexin IV (36-kDa zymogen granule membrane) Q5U362 15.1 2.2 20.2 1.3 0.038 2706 Choline dehydrogenase Q6UPE0 5.6 0.5 8.6 1.1 0.016 3005 Bendless protein (Ubiquitin-conjugating enezyme E2) Q9EQX9 4.2 0.4 5.9 0.8 0.047 <	2206	3-hydroxyanthranilate 3,4-dioxygenase	P46953	9.0	2.1	18.2	3.0	0.013
SuperiorCarbanoyl-phosphate synthetaseP077567.51.815.02.90.023908Carbamoyl-phosphate synthetaseP077568.03.90.50.30.0442608Dipeptidase 3 (rat)Q5U2X46.40.78.60.40.0065302ArginaseP0782469.59.041.69.60.0286504Homogentisate 1,2-dioxygenaseQ6AYR012.42.621.73.70.032 <i>Miscellaneous</i> NN4.80.77.81.20.0201203Annexin IV (36-kDa zymogen granule membrane)Q5U36215.12.220.21.30.0382706Choline dehydrogenaseQ6UPE05.60.58.61.10.0163005Bendless protein (Ubiquitin-conjugating enezyme E2)Q9EQX94.20.45.90.80.0474810Formyltetrahydrofolate dehydrogenaseP2345769.64.058.04.80.0486209Thyroid hormone sulphotransferaseP5284739.84.927.12.50.0186802Serotransferrin, Liver regeneration related protein LLRG03P1234651.67.134.84.20.0347302Dynamin-1-like proteinO3530323.33.710.72.00.0488508Betaine-homocysteine S-methyltransferase 1O0917147.721.5132.837.20.038	7901	Carbamoyl-phosphate synthetase	P07756	8.1	1.3	30.3	9.4	0.018
908 Carbamoyl-phosphate synthetase P07756 8.0 3.9 0.5 0.3 0.044 2608 Dipeptidase 3 (rat) Q5U2X4 6.4 0.7 8.6 0.4 0.006 5302 Arginase P07824 69.5 9.0 41.6 9.6 0.028 6504 Homogentisate 1,2-dioxygenase Q6AYR0 12.4 2.6 21.7 3.7 0.032 Miscellaneous N VINK 4.8 0.7 7.8 1.2 0.020 1203 Annexin IV (36-kDa zymogen granule membrane) Q5U362 15.1 2.2 20.2 1.3 0.038 2706 Choline dehydrogenase Q6UPE0 5.6 0.5 8.6 1.1 0.016 3005 Bendless protein (Ubiquitin-conjugating enezyme E2) Q9EQX9 4.2 0.4 5.9 0.8 0.047 4810 Formyltetrahydrofolate dehydrogenase P23457 69.6 4.0 58.0 4.8 0.048 6209 Thyroid hormone sulphotransferase P52847 39.8 4.9 27.1 2.5 0.018 <t< td=""><td>5902</td><td>Carbamoyl-phosphate synthetase</td><td>P07756</td><td>7.5</td><td>1.8</td><td>15.0</td><td>2.9</td><td>0.023</td></t<>	5902	Carbamoyl-phosphate synthetase	P07756	7.5	1.8	15.0	2.9	0.023
2608Dipeptidase 3 (rat)Q5U2X46.40.78.60.40.0065302ArginaseP0782469.59.041.69.60.0286504Homogentisate 1,2-dioxygenaseQ6AYR012.42.621.73.70.032 <i>Miscellaneous</i> 1007BAB24222 (Mus musculus)UNK4.80.77.81.20.0201203Annexin IV (36-kDa zymogen granule membrane)Q5U36215.12.220.21.30.0382706Choline dehydrogenaseQ6UPE05.60.58.61.10.0163005Bendless protein (Ubiquitin-conjugating enezyme E2)Q9EQX94.20.45.90.80.0474810Formyltetrahydrofolate dehydrogenaseEC 1.5.1.6)P280373.80.66.21.00.03553083-alpha-hydroxysteroid dehydrogenaseP5284739.84.927.12.50.0186802Serotransferrin, Liver regeneration related protein LLRG03P1234651.67.134.84.20.0347302Dynamin-1-like protein03530323.33.710.72.00.0048508Betaine-homocysteine S-methyltransferase 100917147.721.5132.837.20.038	908	Carbamoyl-phosphate synthetase	P07756	8.0	3.9	0.5	0.3	0.044
5302ArginaseP0782469.59.041.69.60.0286504Homogentisate 1,2-dioxygenaseQ6AYR012.42.621.73.70.032Miscellaneous1007BAB24222 (Mus musculus)UNK4.80.77.81.20.0201203Annexin IV (36-kDa zymogen granule membrane)Q5U36215.12.220.21.30.0382706Choline dehydrogenaseQ6UPE05.60.58.61.10.0163005Bendless protein (Ubiquitin-conjugating enezyme E2)Q9EQX94.20.45.90.80.0474810Formyltetrahydrofolate dehydrogenaseP2345769.64.058.04.80.0486209Thyroid hormone sulphotransferaseP5284739.84.927.12.50.0186802Serotransferrin, Liver regeneration related protein LLRG03P1234651.67.134.84.20.0347302Dynamin-1-like proteinO3530323.33.710.72.00.0048508Betaine-homocysteine S-methyltransferase 1O0917147.721.5132.837.20.038	2608	Dipeptidase 3 (rat)	Q5U2X4	6.4	0.7	8.6	0.4	0.006
6504Homogentisate 1,2-dioxygenaseQ6AYR012.42.621.73.70.032MiscellaneousMiscellaneousUNK4.80.77.81.20.0201007BAB24222 (Mus musculus)UNK4.80.77.81.20.0201203Annexin IV (36-kDa zymogen granule membrane)Q5U36215.12.220.21.30.0382706Choline dehydrogenaseQ6UPE05.60.58.61.10.0163005Bendless protein (Ubiquitin-conjugating enezyme E2)Q9EQX94.20.45.90.80.0474810Formyltetrahydrofolate dehydrogenase (EC 1.5.1.6)P280373.80.66.21.00.03553083-alpha-hydroxysteroid dehydrogenaseP2345769.64.058.04.80.0486209Thyroid hormone sulphotransferaseP5284739.84.927.12.50.0186802Serotransferrin, Liver regeneration related protein LLRG03P1234651.67.134.84.20.0347302Dynamin-1-like proteinO3530323.33.710.72.00.0048508Betaine-homocysteine S-methyltransferase 1O0917147.721.5132.837.20.038	5302	Arginase	P07824	69.5	9.0	41.6	9.6	0.028
Miscellaneous 1007 BAB24222 (Mus musculus) UNK 4.8 0.7 7.8 1.2 0.020 1203 Annexin IV (36-kDa zymogen granule membrane) Q5U362 15.1 2.2 20.2 1.3 0.038 2706 Choline dehydrogenase Q6UPE0 5.6 0.5 8.6 1.1 0.016 3005 Bendless protein (Ubiquitin-conjugating enezyme E2) Q9EQX9 4.2 0.4 5.9 0.8 0.047 4810 Formyltetrahydrofolate dehydrogenase (EC 1.5.1.6) P28037 3.8 0.6 6.2 1.0 0.035 5308 3-alpha-hydroxysteroid dehydrogenase P23457 69.6 4.0 58.0 4.8 0.048 6209 Thyroid hormone sulphotransferase P52847 39.8 4.9 27.1 2.5 0.018 6802 Serotransferrin, Liver regeneration related protein LLRG03 P12346 51.6 7.1 34.8 4.2 0.034 7302 Dynamin-1-like protein O35303 23.3 3.7 10.7 2.0 0.004 8508 Betaine–homocysteine S-methyltransfer	6504	Homogentisate 1,2-dioxygenase	Q6AYR0	12.4	2.6	21.7	3.7	0.032
1007BAB24222 (Mus musculus)UNK4.80.77.81.20.0201203Annexin IV (36-kDa zymogen granule membrane)Q5U36215.12.220.21.30.0382706Choline dehydrogenaseQ6UPE05.60.58.61.10.0163005Bendless protein (Ubiquitin-conjugating enezyme E2)Q9EQX94.20.45.90.80.0474810Formyltetrahydrofolate dehydrogenase (EC 1.5.1.6)P280373.80.66.21.00.03553083-alpha-hydroxysteroid dehydrogenaseP2345769.64.058.04.80.0486209Thyroid hormone sulphotransferaseP5284739.84.927.12.50.0186802Serotransferrin, Liver regeneration related protein LLRG03P1234651.67.134.84.20.0347302Dynamin-1-like proteinO3530323.33.710.72.00.0048508Betaine-homocysteine S-methyltransferase 1O0917147.721.5132.837.20.038	Miscellaneou	s						
1203Annexin IV (36-kDa zymogen granule membrane)Q5U36215.12.220.21.30.0382706Choline dehydrogenaseQ6UPE05.60.58.61.10.0163005Bendless protein (Ubiquitin-conjugating enezyme E2)Q9EQX94.20.45.90.80.0474810Formyltetrahydrofolate dehydrogenase (EC 1.5.1.6)P280373.80.66.21.00.03553083-alpha-hydroxysteroid dehydrogenaseP2345769.64.058.04.80.0486209Thyroid hormone sulphotransferaseP5284739.84.927.12.50.0186802Serotransferrin, Liver regeneration related protein LLRG03P1234651.67.134.84.20.0347302Dynamin-1-like proteinO3530323.33.710.72.00.0048508Betaine-homocysteine S-methyltransferase 1O0917147.721.5132.837.20.038	1007	BAB24222 (Mus musculus)	UNK	4.8	0.7	7.8	1.2	0.020
2706Choline dehydrogenaseQ6UPE05.60.58.61.10.0163005Bendless protein (Ubiquitin-conjugating enezyme E2)Q9EQX94.20.45.90.80.0474810Formyltetrahydrofolate dehydrogenase (EC 1.5.1.6)P280373.80.66.21.00.03553083-alpha-hydroxysteroid dehydrogenaseP2345769.64.058.04.80.0486209Thyroid hormone sulphotransferaseP5284739.84.927.12.50.0186802Serotransferrin, Liver regeneration related protein LLRG03P1234651.67.134.84.20.0347302Dynamin-1-like proteinO3530323.33.710.72.00.0048508Betaine-homocysteine S-methyltransferase 1O0917147.721.5132.837.20.038	1203	Annexin IV (36-kDa zymogen granule membrane)	Q5U362	15.1	2.2	20.2	1.3	0.038
3005 Bendless protein (Ubiquitin-conjugating enezyme E2) Q9EQX9 4.2 0.4 5.9 0.8 0.047 4810 Formyltetrahydrofolate dehydrogenase (EC 1.5.1.6) P28037 3.8 0.6 6.2 1.0 0.035 5308 3-alpha-hydroxysteroid dehydrogenase P23457 69.6 4.0 58.0 4.8 0.048 6209 Thyroid hormone sulphotransferase P52847 39.8 4.9 27.1 2.5 0.018 6802 Serotransferrin, Liver regeneration related protein LLRG03 P12346 51.6 7.1 34.8 4.2 0.034 7302 Dynamin-1-like protein O35303 23.3 3.7 10.7 2.0 0.004 8508 Betaine-homocysteine S-methyltransferase 1 O09171 47.7 21.5 132.8 37.2 0.038	2706	Choline dehydrogenase	O6UPE0	5.6	0.5	8.6	1.1	0.016
4810 Formyltetrahydrofolate dehydrogenase (EC 1.5.1.6) P28037 3.8 0.6 6.2 1.0 0.035 5308 3-alpha-hydroxysteroid dehydrogenase P23457 69.6 4.0 58.0 4.8 0.048 6209 Thyroid hormone sulphotransferase P52847 39.8 4.9 27.1 2.5 0.018 6802 Serotransferrin, Liver regeneration related protein LLRG03 P12346 51.6 7.1 34.8 4.2 0.034 7302 Dynamin-1-like protein O35303 23.3 3.7 10.7 2.0 0.004 8508 Betaine-homocysteine S-methyltransferase 1 O09171 47.7 21.5 132.8 37.2 0.038	3005	Bendless protein (Ubiquitin-conjugating enezyme E2)	Q9EQX9	4.2	0.4	5.9	0.8	0.047
5308 3-alpha-hydroxysteroid dehydrogenase P23457 69.6 4.0 58.0 4.8 0.048 6209 Thyroid hormone sulphotransferase P52847 39.8 4.9 27.1 2.5 0.018 6802 Serotransferrin, Liver regeneration related protein LLRG03 P12346 51.6 7.1 34.8 4.2 0.034 7302 Dynamin-1-like protein O35303 23.3 3.7 10.7 2.0 0.004 8508 Betaine-homocysteine S-methyltransferase 1 O09171 47.7 21.5 132.8 37.2 0.038	4810	Formyltetrahydrofolate dehydrogenase (EC 1.5.1.6)	P28037	3.8	0.6	6.2	1.0	0.035
6209 Thyroid hormone sulphotransferase P52847 39.8 4.9 27.1 2.5 0.018 6802 Serotransferrin, Liver regeneration related protein LLRG03 P12346 51.6 7.1 34.8 4.2 0.034 7302 Dynamin-1-like protein O35303 23.3 3.7 10.7 2.0 0.004 8508 Betaine-homocysteine S-methyltransferase 1 O09171 47.7 21.5 132.8 37.2 0.038	5308	3-alpha-hydroxysteroid dehydrogenase	P23457	69.6	4.0	58.0	4.8	0.048
6802 Serotransferrin, Liver regeneration related protein LLRG03 P12346 51.6 7.1 34.8 4.2 0.034 7302 Dynamin-1-like protein O35303 23.3 3.7 10.7 2.0 0.004 8508 Betaine-homocysteine S-methyltransferase 1 O09171 47.7 21.5 132.8 37.2 0.038	6209	Thyroid hormone sulphotransferase	P52847	39.8	4.9	27.1	2.5	0.018
7302 Dynamin-1-like protein O35303 23.3 3.7 10.7 2.0 0.004 8508 Betaine-homocysteine S-methyltransferase 1 O09171 47.7 21.5 132.8 37.2 0.038	6802	Serotransferrin, Liver regeneration related protein LLRG03	P12346	51.6	7.1	34.8	4.2	0.034
8508 Betaine-homocysteine S-methyltransferase 1 009171 47.7 21.5 132.8 37.2 0.038	7302	Dynamin-1-like protein	O35303	23.3	3.7	10.7	2.0	0.004
= 1.1.1.1 10.100 Julion of the manufacture o	8508	Betaine-homocysteine S-methyltransferase 1	O09171	47.7	21.5	132.8	37.2	0.038

Offspring were from dams fed complete (CON) or methyl-deficient (MD) diets. Data are mean pixel density \pm SEM, n = 8 in each group. Data compared by Student's *t* test

important to note that the tissues used in the present study were derived from animals that had been subjected to a glucose tolerance test 3 h earlier. As a result, the liver will have been insulin stimulated in vivo, and since insulin specifically inhibits transcription of the PEPCK gene (Granner et al. 1983), changes in the rate of transcription may be masked. There is no evidence for changes in the abundance of proteins associated with lipid metabolism in the early MD offspring, unlike those of dams exposed to HF or LP diets. This is also apparent in the expression of mRNAs for both key enzymes and regulators. For example, HF diets fed throughout gestation upregulate the expression of PPARalpha and L-CPT-1 in the liver (Zhang et al. 2009). The

Table 2	Hepatic	proteome	of	the male	offspring	at	12	months	of	age
---------	---------	----------	----	----------	-----------	----	----	--------	----	-----

ID	NCBI	CON		MD		Р
		Mean	SEM	Mean	SEM	
lism						
L-lactate dehydrogenase (EC 1.1.1.27) chain M	P04642	426.3	52.5	264.4	28.7	0.022
Cytidylate kinase	Q4KM73	58.2	5.0	43.9	3.5	0.049
UDP-glucose pyrophosphorylase 2.	Q4V8I9	158.6	18.9	104.2	13.8	0.045
Electron transfer flavoprotein subunit beta (beta-ETF)	Q68FU3	145.2	5.7	178.8	13.5	0.026
<i>fence</i>						
Catalase (EC 1.11.1.6).	P04762	142.6	9.4	85.4	17.9	0.009
HAGH (Hydroxyacylglutathione hydrolase) protein	O35952	10.8	2.6	20.9	3.1	0.023
Selenium binding protein 2.	Q8VIF7	235.9	23.1	341.8	41.6	0.031
5-oxoprolinase (ATP-hydrolysing) (EC 3.5.2.9)	P97608	9.4	1.6	5.2	0.8	0.046
l peptide metabolism						
Ornithine carbamoyltransferase (EC 2.1.3.3) precursor	P00481	102.2	8.5	69.5	3.5	0.006
Acylaminoacyl peptidase (EC 3.4.19.1)	P13676	8.8	1.9	16.9	3.0	0.033
Aspartate transaminase (EC 2.6.1.1), cytosolic	P13221	288.6	26.7	209.5	18.5	0.038
Aldehyde dehydrogenase 9 family, member A1	Q9JLJ3	318.0	29.6	502.1	63.7	0.012
Mannosidase, alpha, class 2C, member 1.	Q5M9I2	4.3	0.7	7.6	1.0	0.015
3-oxo-5-beta-steroid 4-dehydrogenase (EC 1.3.99.6)	P31210	56.4	10.3	125.6	27.1	0.020
3-oxo-5-beta-steroid 4-dehydrogenase (EC 1.3.99.6)	P31210	408.9	54.8	604.9	54.5	0.026
	ID <i>lism</i> L-lactate dehydrogenase (EC 1.1.1.27) chain M Cytidylate kinase UDP-glucose pyrophosphorylase 2. Electron transfer flavoprotein subunit beta (beta-ETF) <i>fence</i> Catalase (EC 1.11.1.6). HAGH (Hydroxyacylglutathione hydrolase) protein Selenium binding protein 2. 5-oxoprolinase (ATP-hydrolysing) (EC 3.5.2.9) <i>d peptide metabolism</i> Ornithine carbamoyltransferase (EC 2.1.3.3) precursor Acylaminoacyl peptidase (EC 3.4.19.1) Aspartate transaminase (EC 2.6.1.1), cytosolic Aldehyde dehydrogenase 9 family, member A1 Mannosidase, alpha, class 2C, member 1. 3-oxo-5-beta-steroid 4-dehydrogenase (EC 1.3.99.6) 3-oxo-5-beta-steroid 4-dehydrogenase (EC 1.3.99.6)	IDNCBIlismL-lactate dehydrogenase (EC 1.1.1.27) chain MP04642Cytidylate kinaseQ4KM73UDP-glucose pyrophosphorylase 2.Q4V819Electron transfer flavoprotein subunit beta (beta-ETF)Q68FU3fenceCatalase (EC 1.11.1.6).P04762HAGH (Hydroxyacylglutathione hydrolase) proteinO35952Selenium binding protein 2.Q8VIF75-oxoprolinase (ATP-hydrolysing) (EC 3.5.2.9)P97608d peptide metabolismOrnithine carbamoyltransferase (EC 2.1.3.3) precursorP00481Acylaminoacyl peptidase (EC 3.4.19.1)P13676Aspartate transaminase (EC 2.6.1.1), cytosolicP13221Aldehyde dehydrogenase 9 family, member A1Q9JLJ3Mannosidase, alpha, class 2C, member 1.Q5M9123-oxo-5-beta-steroid 4-dehydrogenase (EC 1.3.99.6)P31210	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$

Offspring were from dams fed complete (CON) or methyl-deficient (MD) diets. Data are mean pixel density \pm SEM, n = 9 for CON and n = 7 for MD. Data compared by Student's *t* test

Table 3 Gene expression in the liver of male offspring at 6 months of age

Gene	n	CON		MD	Р	
		Mean	SEM	Mean	SEM	
PEPCK(T)	16	3.39	0.31	4.07	0.35	0.157
GAPDH(T)	16	2.80	0.10	3.03	0.13	0.162
UGDH(T)	8	5.69	0.14	6.03	0.28	0.298
PPAR-alpha	8	5.39	0.26	5.90	0.45	0.340
PPAR-gamma	16	6.06	0.61	6.36	0.47	0.704
SREBP-1c	16	1.48	0.13	1.61	0.12	0.461
GccR	16	3.69	0.13	3.76	0.17	0.719
ACC-1	8	5.88	0.40	6.06	0.07	0.817
L-CPT	16	2.53	0.15	2.68	0.17	0.521

Offspring were from dams fed complete (CON) or methyl-deficient (MD) diets. All data are expressed in arbitrary units as relative expression corrected for 18S rRNA. n = number of animals, 1 per litter chosen at random from the total pool of 18 litters (CON) and 17 litters (MD). Data compared by Student's *t* test

Enzyme activity nmol/min/mg protein	CON		MD	Р	
	Mean	SEM	Mean	SEM	
PEPCK	0.34	0.08	0.39	0.06	0.649
GAPDH	199.7	10.5	181.7	7.6	0.183

Table 4 Enzyme activities in liver homogenates prepared from male offspring at 6 months of age

Offspring were from dams fed complete (CON) or methyl-deficient (MD) diets. The homogenate was prepared from a sample of the same liver used for the proteome analysis. Data compared by Student's t test, n = 8

expression of both ACC-1 and L-CPT-1 is also increased in LP offspring (Maloney et al. 2003, 2007) possibly mediated by an increase in PPAR-alpha expression (Lillycrop et al. 2005). In the LP model, there are also increases in SREBP-1c expression mediated by glucocorticoid signalling (Erhuma et al. 2009). However, in the early MD model, there is no evidence for changes in expression of ACC-1 and L-CPT-1 mRNAs or in the mRNAs for PPARalpha, SREBP-1c or glucocorticoid receptor. This important difference suggests that the events programming hepatic fat metabolism through PPAR isoforms or SREBP-1c occur later in foetal development.

In addition to proteins involved in carbohydrate metabolism and the management of glycogen reserves, the list of differentially expressed proteins associated with energy metabolism also includes proteins with functions in oxidative metabolism. These include proteins that transfer substrates to the mitochondria, suggesting that the change in metabolism extends beyond carbohydrates to include oxidative metabolism by the mitochondrion. Further evidence for a change in oxidative metabolism comes from the differential abundance of a group of proteins associated with antioxidant defence. These proteins are produced in response to free radicals, an unwanted and harmful byproduct of metabolic activity, and correlate with changes in mitochondrial activity (Aiken et al. 2008). The products of oxidative damage include proteins and lipids, and the processes that remove them are represented in the group of proteins associated with amino acid and peptide metabolism. Denatured proteins are rapidly degraded by the proteosome (Breusing and Grune 2008), and the resulting peptides are hydrolysed to amino acids by acylaminoacyl peptidase (Shimizu et al. 2004). Peroxiredoxin-6 (Prdx6) also has an important role in antioxidant defence through the metabolism of peroxidised membrane phospholipids (Roede et al. 2009). These results suggest that the differential abundance of proteins associated with antioxidant defence, amino acid and peptide metabolism is probably linked by changes in oxidative metabolism and the production of free radicals. Changes in antioxidant defence are a common feature in the proteome of many animal models of both insulin resistance (Schmid et al. 2004) and metabolic programming (Lillycrop et al. 2010; Mortensen et al. 2010a, b). In these models, alterations in mitochondrial function underlie the change in metabolic activity. There is also direct evidence for programming of mitochondrial function by methyl deficiency during development. The offspring of dams subjected to methyl-deficient diets during gestation and lactation also exhibit changes in oxidative metabolism of the myocardium, mediated through imbalanced methylation/acetylation of PGC-1 α (Garcia et al. 2011). These changes in both the methylation and acetylation of the PGC-1 α protein are strikingly similar to the present findings where low molecular weight modifications influence the abundance of both PGK1 and GAPDH isoforms. These cumulative data suggest that the mitochondria may be a major target in the early MD model of metabolic programming.

The mitochondria of the developing foetus are derived exclusively from the oocyte. Having established the full complement of mitochondria in the fully grown oocyte, there is no further increase in the mitochondrial population during early development (Dumollard et al. 2007). Changes in maternal metabolism such as those produced by maternal diabetes have been shown to modify mitochondrial function in the oocyte (Wang and Moley 2010). Maternal diet also modifies mitochondrial potential. In the case of mice fed high-fat diets, there was a fall in mitochondrial DNA content and biogenesis in the preimplantation embryo, and the obese dams were less able to support blastocyst formation (Igosheva et al. 2010). A reduction in the litter size was also a feature of the early MD dams (CON 12.9 vs. MD 10.7 pups per litter) (Maloney et al. 2011), and it is possible that the extensive changes in lipid metabolism in the maternal liver of dams fed the MD diet (McNeil et al. 2008) may be affecting oocyte quality and mitochondria in the same way as the high-fat diets. The MD diet may be selecting those embryos with a higher mitochondrial density leading to long-term changes in metabolism with the posttranslational modification of proteins acting as a possible regulatory mechanism.

Acknowledgments This study is supported by NIH (U01 HD044638 to KDS) as a component of the NICHD Cooperative Program on Female Health and Egg Quality and by the Scottish Government Rural and Environmental Research and Analysis Directorate (RERAD) as part of the core funding of the Rowett Institute of Nutrition and Health (WDR).We wish to express our thanks to staff from Bioresources Unit for animal care.

References

- Aiken CE, Cindrova-Davies T, Johnson MH (2008) Variations in mouse mitochondrial DNA copy number from fertilization to birth are associated with oxidative stress. Reprod Biomed Online 17:806–813
- Bogdarina I, Welham S, King PJ, Burns SP, Clark AJL (2007) Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res 100:520–526
- Bogdarina I, Haase A, Langley-Evans S, Clark AJL (2010) Glucocorticoid effects on the programming of AT1b angiotensin receptor gene methylation and expression in the rat. PLoS ONE 5:e9237
- Breusing N, Grune T (2008) Regulation of proteasome-mediated protein degradation during oxidative stress and aging. Biol Chem 389:203–209
- Desai M, Byrne CD, Meeran K, Martenz ND, Bloom SR, Hales CN (1997) Regulation of hepatic enzymes and insulin levels in offspring of rat dams fed a reduced-protein diet. Am J Physiol 273:G899–G904
- Dumollard R, Duchen M, Carroll J (2007) The role of mitochondrial function in the oocyte and embryo. In: Justin CS (ed) Current topics in developmental biology, The mitochondrion in the germline and early development. Academic Press, USA, pp 21–49
- Erhuma A, McMullen S, Langley-Evans S, Bennett A (2009) Feeding pregnant rats a low-protein diet alters the hepatic expression of SREBP-1c in their offspring via a glucocorticoid-related mechanism. Endocrine 36:333–338
- Fernandez-Gonzalez R, Moreira P, Bilbao A, Jiminez A, Perez-Crespo M, Ramirez MA, De Fonseca FR, Pintado B, Gutierrez-Adan A (2004) Long-term effect of in vitro culture of mouse embryos with serum on mRNA expression of imprinting genes, development, and behavior. Proc Nat Acad Sci USA 101:5880– 5885
- Garcia MM, Gueant-Rodriguez RM, Pooya S et al (2011) Methyl donor deficiency induces cardiomyopathy through altered methylation/acetylation of PGC-1alpha by PRMT1 and SIRT1. J Pathol 255:324–335
- Granner D, Andreone T, Sasaki K, Beale E (1983) Inhibition of transcription of the phosphoenolpyruvate carboxykinase gene by insulin. Nature 305:549–551
- Guan KL, Xiong Y (2011) Regulation of intermediary metabolism by protein acetylation. Trends Biochem Sci 36:108–116
- Hochberg Z, Feil R, Constancia M et al (2010) Child health, developmental plasticity, and epigenetic programming. Endocr Rev 32:159–224
- Igosheva N, Abramov AY, Poston L, Eckert JJ, Fleming TP, Duchen MR, McConnell J (2010) Maternal diet-induced obesity alters mitochondrial activity and redox status in mouse oocytes and zygotes. PLoS ONE 5:e10074
- Kwong WY, Miller DJ, Wilkins AP, Dear MS, Wright JN, Osmond C, Zhang J, Fleming TP (2007) Maternal low protein diet restricted to the preimplantation period induces a gender-specific change on hepatic gene expression in rat fetuses. Mol Reprod Dev 74:48–56
- Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC (2005) Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr 135:1382–1386

- Lillycrop KA, Rodford J, Garratt ES, Slater-Jefferies JL, Godfrey KM, Gluckman PD, Hanson MA, Burdge GC (2010) Maternal protein restriction with or without folic acid supplementation during pregnancy alters the hepatic transcriptome in adult male rats. Br J Nutr 103:1711–1719
- Maloney CA, Gosby AK, Phuyal JL, Denyer GS, Bryson JM, Caterson ID (2003) Site-specific changes in the expression of fatpartitioning genes in weanling rats exposed to a low-protein diet in utero. Obesity Res 11:461–468
- Maloney CA, Lilley C, Cruickshank M, McKinnon C, Hay SM, Rees WD (2005) The expression of growth-arrest genes in the liver and kidney of the protein-restricted rat fetus. Br J Nutr 94:12–18
- Maloney CA, Lilley C, Czopek A, Hay SM, Rees WD (2007) Interactions between protein and vegetable oils in the maternal diet determine the programming of the insulin axis in the rat. Br J Nutr 97:912–920
- Maloney CA, Hay SM, Young LE, Sinclair KD, Rees WD (2011) A methyl-deficient diet fed to rat dams during the peri-conception period programs glucose homeostasis in adult male but not female offspring. J Nutr 141:95–100
- McNeil CJ, Hay SM, Rucklidge G, Reid M, Duncan G, Maloney CA, Rees WD (2008) Disruption of lipid metabolism in the liver of the pregnant rat fed folate deficient and methyl donor deficient diets. Br J Nutr 99:262–271
- Mortensen OH, Olsen HL, Frandsen L, Nielsen PE, Nielsen FC, Grunnet N, Quistorff B (2010a) A maternal low protein diet has pronounced effects on mitochondrial gene expression in offspring liver and skeletal muscle; protective effect of taurine. J Biomed Sci 17(Suppl 1):S38
- Mortensen OH, Olsen HL, Frandsen L, Nielsen PE, Nielsen FC, Grunnet N, Quistorff B (2010b) Gestational protein restriction in mice has pronounced effects on gene expression in newborn offspring's liver and skeletal muscle; protective effect of taurine. Pediatr Res 67:47–53
- Nicholls C, Li H, Liu JP (2011) GAPDH: a common enzyme with uncommon functions. Clin Exp Pharmacol Physiol 39:674–679
- Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR (1998) Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J Clin Invest 101:2174–2181
- Nyirenda MJ, Welberg LA, Seckl JR (2001) Programming hyperglycaemia in the rat through prenatal exposure to glucocorticoids-fetal effect or maternal influence? J Endocrinol 170:653– 660
- Petrescu I, Bojan O, Saied M, Barzu O, Schmidt F, Kuhnle HF (1979) Determination of phosphoenolpyruvate carboxykinase activity with deoxyguanosine 5'-diphosphate as nucleotide substrate. Anal Biochem 96:279–281
- Rees WD, Hay SM, Cruickshank M, Reusens B, Remacle C, Antipatis C, Grant G (2006) Maternal protein intake in the pregnant rat programs the insulin axis and body composition in the offspring. Metabolism 55:642–649
- Roede JR, Orlicky DJ, Fisher AB, Petersen DR (2009) Overexpression of peroxiredoxin 6 does not prevent ethanol-mediated oxidative stress and may play a role in hepatic lipid accumulation. J Pharmacol Exp Ther 330:79–88
- Sandovici I, Smith NH, Nitert MD et al (2011) Maternal diet and aging alter the epigenetic control of a promoter-enhancer interaction at the Hnf4a gene in rat pancreatic islets. Proc Natl Acad Sci USA 108:5449–5454
- Santos F, Dean W (2004) Epigenetic reprogramming during early development in mammals. Reproduction 127:643–651
- Schmid GM, Converset V, Walter N, Sennitt MV, Leung KY, Byers H, Ward M, Hochstrasser DF, Cawthorne MA, Sanchez JC (2004) Effect of high-fat diet on the expression of proteins in

muscle, adipose tissues, and liver of C57BL/6 mice. Proteomics 4:2270–2282

- Scott KA, Yamazaki Y, Yamamoto M, Lin Y, Melhorn SJ, Krause EG, Woods SC, Yanagimachi R, Sakai RR, Tamashiro KLK (2010) Glucose parameters are altered in mouse offspring produced by assisted reproductive technologies and somatic cell nuclear transfer. Biol Reprod 83:220–227
- Shimizu K, Kiuchi Y, Ando K, Hayakawa M, Kikugawa K (2004) Coordination of oxidized protein hydrolase and the proteasome in the clearance of cytotoxic denatured proteins. Biochem Biophys Res Commun 324:140–146
- Sinclair KD, Allegrucci C, Singh R et al (2007a) DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status. Proc Natl Acad Sci USA 104:19351–19356
- Sinclair KD, Lea RG, Rees WD, Young LE (2007b) The developmental origins of health and disease: current theories and epigenetic mechanisms. Soc Reprod Fertil Suppl 64:425–443
- Strakovsky RS, Zhang X, Zhou D, Pan YX (2011) Gestational high fat diet programs hepatic phosphoenolpyruvate carboxykinase gene expression and histone modification in neonatal offspring rats. J Physiol 589:2707–2717
- Tamashiro KL, Wakayama T, Yamazaki Y, Akutsu H, Woods SC, Kondo S, Yanagimachi R, Sakai RR (2003) Phenotype of cloned mice: development, behavior, and physiology. Exp Biol Med (Maywood) 228:1193–1200

- van Straten EME, Bloks VW, Huijkman NCA, Baller JFW, Meer HV, Lutjohann D, Kuipers F, Plosch T (2010) The liver X-receptor gene promoter is hypermethylated in a mouse model of prenatal protein restriction. Am J Physiol Regul Integr Comp Physiol 298:R275–R282
- Wang Q, Moley KH (2010) Maternal diabetes and oocyte quality. Mitochondrion 10:403–410
- Waterland RA, Jirtle RL (2003) Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 23:5293–5300
- Waterland RA, Michels KB (2007) Epigenetic epidemiology of the developmental origins hypothesis. Annu Rev Nutr 27:363–388
- Watts LM, Manchem VP, Leedom TA et al (2005) Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54:1846–1853
- Zhang J, Byrne CD (2000) Differential hepatic lobar gene expression in offspring exposed to altered maternal dietary protein intake. Am J Physiol Gastrointest Liver Physiol 278:G128–G136
- Zhang J, Zhang F, Didelot X, Bruce K, Cagampang F, Vatish M, Hanson M, Lehnert H, Ceriello A, Byrne C (2009) Maternal high fat diet during pregnancy and lactation alters hepatic expression of insulin like growth factor-2 and key microRNAs in the adult offspring. BMC Genomics 10:478